The growth of psychopharmacology in the 1990s: Evidence-based practice or irrational exuberance

International Journal of Law and Psychiatry

Volumn 28, Issue 5, 2005, Pages 467-483

  Rosenheck, Robert ^a,b  

^a VA CONNECTICUT HEALTHCARE SYSTEM   (United States)

^b YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDEPRESSANT AGENT; ATYPICAL ANTIPSYCHOTIC AGENT; CLOZAPINE; FLUOXETINE; HALOPERIDOL; NEUROLEPTIC AGENT; OLANZAPINE; PERPHENAZINE; PSYCHOTROPIC AGENT; QUETIAPINE; RISPERIDONE; SEROTONIN UPTAKE INHIBITOR; TRICYCLIC ANTIDEPRESSANT AGENT; ZIPRASIDONE;

ANTICHOLINERGIC EFFECT; BIPOLAR DISORDER; CLINICAL PRACTICE; CLINICAL TRIAL; COST CONTROL; COST OF ILLNESS; DEPRESSION; DIABETES MELLITUS; DIZZINESS; DRUG COST; DRUG EFFICACY; DRUG MANUFACTURE; DRUG MARKETING; DRUG SAFETY; DRUG SCREENING; DRUG TOLERABILITY; EXTRAPYRAMIDAL SYMPTOM; FOOD AND DRUG ADMINISTRATION; GOVERNMENT; HAMILTON SCALE; HEALTH CARE COST; HEALTH CARE SYSTEM; HEART DISEASE; HOSPITAL DISCHARGE; HUMAN; HYPERLIPIDEMIA; MEMORY DISORDER; PSYCHOPHARMACOLOGY; PSYCHOTHERAPY; QUALITY OF LIFE; REVIEW; SCHIZOPHRENIA; SEXUAL DYSFUNCTION; SIDE EFFECT; SUICIDE; TARDIVE DYSKINESIA; WEIGHT GAIN; XEROSTOMIA;

EID: 25144495632     PISSN: 01602527     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijlp.2005.08.005     Document Type: Article

References (78)

1. J. Abramson Overdosed America: The broken promise of American medicine 2004 Harper Collins New York, NY
2. M. Angel The truth about the drug companies: How they deceive us and what to do about it 2004 Random House NewYork, NY
3. Association of Clinical Endocrinologists, North American Association for the Study of Obesity Consensus development conference on antipsychotic drugs and obesity and diabetes Diabetes Care 27 2004 596 601
4. J. Avorn Powerful medicines: The benefits, risks, and costs of prescription drugs 2004 Knopf New York, NY
5. C.B. Baker, M.T. Johnsrud, M.L. Crismon, R.M. Rosenheck, and S.W. Woods Quantitative analysis of sponsorship bias in economic studies of antidepressants British Journal of Psychiatry 183 2003 498 506
6. D. Blumenthal Doctors and drug companies New England Journal of Medicine 351 18 2004 1885 1890
7. P. Breggin, and G.R. Breggin Talking back to prozac: What doctors won't tell you about today's most controversial drug 1995 St. Martin's Press New York
8. D.A. Brent Antidepressants and pediatric depression-the risk of doing nothing New England Journal of Medicine 351 16 2004 1598 1601
9. C.S. Brown, J.S. Markowitz, T.R. Moore, and N.G. Parker Atypical antipsychotics: Part II: Adverse effects, drug interactions, and costs Annals of Pharmacotherapy 33 2 1999 210 217
10. R.V. Burkhauser, and D.C. Stapleton A review of the evidence and its implications for policy change D.C. Stapleton R.V. Burkhauser The decline in employment of people with disabilities 2003 WE Upjohn Institute for Employment Research Kalamazoo, MI 217 258
11. C.U. Correll, S. Leucht, and J.M. Kane Lower risk for tardive dyskinesia associated with second-generation antipsychotics: A systematic review of 1-year studies American Journal of Psychiatry 161 3 2004 414 425
12. F. Davidoff, C.D. DeAngelis, J.M. Drazen, M.G. Nicholls, J. Hoey, and L. Hojgaard International committee of medical journal editors. Sponsorship, authorship and accountability Journal of the American Medical Association 286 2001 2132 2134
13. S.M. Davis, G.G. Koch, C.E. Davis, and L.M. LaVange Statistical approaches to effectiveness measurement and outcome-driven re-randomizations in the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) studies Schizophrenia Bulletin 29 1 2003 57 72
14. K. Deegan, and E. Nasper Return from madness: Psychotherapy with people taking the new antipsychotic medications and emerging from severe, lifelong, and disabling schizophrenia 1996 Jason Aronson New York, NY
15. J.A. DeMasi, R.W. Hansen, and H.G. Grabowski The price of innovation: New estimates of drug development costs Journal of Health Economics 22 2003 325 330
16. Director, Division of Neuropharmacological Drug Products. (1996a). Unpublished memo concerning NDA 20-592 Zyprexa [olanzapine], August 18, 1996, p. 5.
17. Director, Division of Neuropharmacological Drug Products. (1996b). Unpublished memo concerning NDA 20-592 Zyprexa [olanzapine]. August 30, 1996, p. 3.
18. Duggan, M. (2003). Does Medicaid pay too much for prescription drugs? A case study of atypical antipsychotics. NBER Working paper w9626, April 2003. Available at: http://www.nber.org/papers/w9626.
19. S.M. Essock, L.K. Frisman, N.H. Covell, and W. Hargreaves Cost-effectiveness of clozapine compared with conventional antipsychotic medications for patients in state hospitals Archives of General Psychiatry 57 10 2000 987 994
20. R. Frank, E.R. Berndt, J. Donohue, A. Epstein, and M. Rosenthal Trends in direct-to-consumer advertising of prescription drugs http://www.kff.org/ rxdrugs/loader.cfm?url=/commonspot/security/getfile.cfm and PageID=4881 2002
21. N. Freemantle, I.M. Anderson, and P. Young Predictive value of pharmacological activity for the relative efficacy of antidepressant drugs. Meta-regression analysis British Journal of Psychiatry 177 2000 292 302
22. W.M. Glazer, and B.M. Johnstone Pharmacoeconomic evaluation of antipsychotic therapy for schizophrenia Journal of Clinical Psychiatry 58 Suppl 10 1997 50 54
23. J. Glenmullen Prozac Backlash: Overcoming the dangers of prozac, zoloft, paxil, and other antidepressants with safe, effective alternatives 2001 Simon and Shuster New York
24. E. Goode Leading drugs for psychosis come under new scrutiny 2003, May 20 New York Times New York, N.Y. A.1
25. M. Goozner The $800 million pill: The truth behind the cost of new drugs 2003 University of California Press Berkeley, CA
26. J.S. Harman, S. Crystal, J. Walkup, and M. Olfson Trends in elderly patients' office visits for the treatment of depression according to physician specialty: 1985-1999 Journal of Behavioral Health Services and Research 30 3 2003 332 341
27. S.H. Hamilton, D.A. Revicki, E.T. Edgell, L.A. Genduso, and G. Tollefson Clinical and economic outcomes of olanzapine compared with haloperidol for schizophrenia-Results from a randomised clinical trial PharmacoEconomics 15 5 1999 469 480
28. D. Healy Let them eat prozac: The unhealthy relationship between the pharmaceutical industry and depression 2004 New York University Press New York
29. Hypericum Depression Trial Study Group Effect of Hypericum perforatum (St John's wort) in major depressive disorder: A randomized controlled trial Journal of the American Medical Association 287 14 2002 1807 1814
30. J.N. Jureidini, C.J. Doecke, P.R. Mansfield, M.M. Haby, D.B. Menkes, and A.L. Tonkin Efficacy and safety of antidepressants for children and adolescents BMJ 328 7444 2004 879 883
31. J. Kane, G. Honigfeld, J. Singer, and H. Meltzer Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine Archives of General Psychiatry 45 9 1988 789 796
32. W. Katon, M. Von Korff, E. Lin, E. Walker, G.E. Simon, and T. Bush Collaborative management to achieve treatment guidelines. Impact on depression in primary care Journal of the American Medical Association 273 13 1995 1026 1031
33. J. Kassirer On the take: How medicine's complicity with big business can endanger your health 2004 Oxford University Press New York, NY
34. A. Khan, H.A. Warner, and W.A. Brown Symptom reduction and suicide risk in patients treated with placebo in antidepressant clinical trials: an analysis of the Food and Drug Administration database Archives of General Psychiatry 57 4 2001 311 317
35. I. Kirsh, T.J. Moore, A. Scoboria, and S.S. Nicholls The Emperor's new drugs: An analysis of antidepressant medication data submitted to the US Food and Drug Administration Prevention and Treatment 5 2002 (article 23. Available at: http://www.journals.apa.org/prevention/volume1/pre0010002a.html )
36. P. Kramer Listening to Prozac 1997 Penguin New York
37. P.W. Lavori Clinical trials in psychiatry: Should protocol deviation censor patient data? Neuropsychopharmacology 6 1 1992 39 48
38. D. Leslie, and R.A. Rosenheck Fifth annual report on pharmacotherapy of schizophrenia in the Department of Veterans Affairs 2004 Northeast Program Evaluation Center West Haven, CT
39. S. Leucht, T.R. Barnes, W. Kissling, R.R. Engel, lC. Correl, and J.M. Kane Relapse prevention in schizophrenia with new-generation antipsychotics: A systematic review and exploratory meta-analysis of randomized, controlled trials American Journal of Psychiatry 160 2003 1209 1222
40. Lewis, S., Davies, L., Jones, P., Barnes, T., Murray, R., & Kerwin, R., et al. (2005). Randomized controlled trials of conventional antipsychotic versus new atypical drugs, and new atypical drugs versus clozapine, in people with schizophrenia responding poorly to, or intolerant of, current drug treatment. National Coordinating Centre for Health Technology Assessment. Report 96/19/06.
41. E.H. Lin, G.E. Simon, W.J. Katon, J.E. Russo, M. Von Korff, and T.M. Bush Can enhanced acute-phase treatment of depression improve long-term outcomes? A report of randomized trials in primary care American Journal of Psychiatry 156 4 1999 643 645
42. J. March, S. Silva, S. Petrycki, J. Curry, K. Wells, and J. Fairbank Treatment for Adolescents With Depression Study (TADS) team. Fluoxetine, cognitive-behavioral therapy, and their combination for adolescents with depression: Treatment for Adolescents With Depression Study (TADS) randomized controlled trial Journal of the American Medical Association 292 7 2004 807 820
43. S.R. Marder, S.M. Essock, A.L. Miller, R.W. Buchanan, D.E. Casey, and J.M. Davis Physical health monitoring of patients with schizophrenia American Journal of Psychiatry 161 8 2004 1334 1349
44. J.S. Markowitz, C.S. Brown, and T.R. Moore Atypical antipsychotics. Part I: Pharmacology, pharmacokinetics, and efficacy Annals of Pharmacotherapy 33 1 1999 73 85
45. H. Melander, J. Ahlqvist-Rastad, G. Meijer, and B. Beermann Evidence b(i)ased medicine-selective reporting from studies sponsored by pharmaceutical industry: Review of studies in new drug applications British Medical Journal 326 7400 2003 1171 1173
46. K.I. Melkersson, A.L. Hulting, and K.E. Brismar Elevated levels of insulin, leptin, and blood lipids in olanzapine-treated patients with schizophrenia or related psychoses Journal of Clinical Psychiatry 61 2000 742 749
47. H.Y. Meltzer, P. Cola, L. Way, P.A. Thompson, B. Bastani, and M.A. Davies Cost-effectiveness of clozapine in neuroleptic resistant schizophrenia American Journal of Psychiatry 150 1993 1630 1638
48. J. Moncrieff Are antidepressants overrated? A review of methodological problems in antidepressant trials Journal of Nervous and Mental Disease 189 5 2001 288 295
49. H. Morgenstern, and W.M. Glazer Identifying risk factors for tardive dyskinesia among long-term outpatients maintained with neuroleptic medications. Results of the Yale Tardive Dyskinesia Study Archives of General Psychiatry 50 9 1993 723 733
50. R. Moynihan Celebrity selling-part two British Medical Journal 325 2002 286
51. National Institute of Health Care Research and Education Foundation Management Prescription Drug Expenditures in 2001: Another Year of Escalating Costs 2002
52. M. Olfson, S.C. Marcus, B. Druss, L. Elinson, T. Tanielian, and H.A. Pincus National trends in the outpatient treatment of depression Journal of the American Medical Association 287 2 2002 203 209
53. M. Olfson, S.C. Marcus, H.A. Pincus, J.M. Zito, J.W. Thompson, and D.A. Zarin Antidepressant prescribing practices of outpatient psychiatrists Archives of General Psychiatry 55 4 1998 310 316
54. M. Olfson, D. Shaffer, S.C. Marcus, and T. Greenberg Relationship between antidepressant medication treatment and suicide in adolescents Archives of General Psychiatry 60 10 2003 978 982
55. H.A. Pincus, T.L. Tanielian, S.C. Marcus, M. Olfson, D.A. Zarin, and J. Thompson Prescribing trends in psychotropic medications: Primary care, psychiatry, and other medical specialties Journal of the American 279 7 1998 526 531
56. F.M. Quitkin, J.G. Rabkin, J. Gerald, J.M. Davis, and D.F. Klein Validity of clinical trials of antidepressants American Journal of Psychiatry 157 3 2000 327 337
57. W.H. Reid, and M. Mason Psychiatric hospital utilization in patients treated with clozpaine for up to 4.5 years in a state mental health care system Journal of Clinical Psychiatry 59 1998 189 194
58. W.H. Reid, M. Mason, and T. Hogan Suicide prevention effects associated with clozapine therapy in schizophrenia and schizoaffective disorder Psychiatric Services 49 8 1998 1029 1033
59. D.A. Revicki, B.R. Luce, J.M. Wechsler, R.E. Brown, and M.A. Adler Cost-effectiveness of clozapine for treatment resistent schizophrenic patients Hospital and Community Psychiatry 41 1990 850 854
60. R.A. Rosenheck Efficacy vs. effectiveness of second generation antipsychotics: Is haloperidol haloperidol without prophylactic anticholinergics as a comparitor Psychiatric Services 56 2005 85 92
61. R. Rosenheck, J. Cramer, E. Allan, J. Erdos, L.K. Frisman, and W. Xu Cost-effectiveness of Clozapine in patients with high and low levels of hospital use Archives of General Psychiatry 56 6 1999 565 572
62. R.A. Rosenheck for the Department of Veterans Affairs, Cooperative Study Group on Clozapine in Refractory Schizophrenia A comparison of clozapine and haloperidol in the treatment of hospitalized patients with refractory schizophrenia New England Journal of Medicine 337 1997 809 815
63. R.A. Rosenheck, D.L. Leslie, and M.E. Sernyak From clinical trials to real-world practice: Use of atypical antipsychotic medication nationally in the Department of Veterans Affairs Medical Care 39 3 2001 302 308
64. R.A. Rosenheck, D. Perlick, S. Bingham, Liu-Mares, J. Collins, S. Warren for the Department of Veterans Affairs Cooperative Study Group on the Cost-Effectiveness of Olanzapine Effectiveness and cost of olanzapine and haloperidol in the treatment of schizophrenia Journal of the American Medical Association 290 2003 2693 2702
65. G.E. Simon, M. VonKorff, J.H. Heiligenstein, D.A. Revicki, L. Grothaus, and W. Katon Initial antidepressant choice in primary care. Effectiveness and cost of fluoxetine vs tricyclic antidepressants Journal of the American Medical Association 275 24 1996 1897 1902
66. M.M. Simpson, R.R. Goetz, M.J. Devlin, S.A. Goetz, and B.T. Walsh Weight gain and antipsychotic medication: Differences between antipsychotic-free and treatment periods Journal of Clinical Psychiatry 62 9 2001 694 700
67. T.S. Stroup, J.P. McEvoy, M.S. Swartz, M.J. Byerly, I.D. Glick, and J.M. Canive The National Institute of Mental Health Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) project: schizophrenia trial design and protocol development Schizophrenia Bulletin 29 2003 15 31
68. D.M. Studdert, M.M. Mello, and T.A. Brennan Financial conflicts of interest in physicians' relationships with the pharmaceutical industry-self regulation in the shadow of federal prosecution New England Journal of Medicine 351 18 2004 1891 1900
69. G.D. Tollefson, and T.M. Sanger Negative symptoms: a path analytic approach to a double-blind, placebo- and haloperidol-controlled clinical trial with olanzapine American Journal of Psychiatry 154 1997 466 474
70. G.D. Tollefson, C.M. Beasley Jr., P.V. Tran, J. Street, J. Krueger, and R.N. Tamura Olanzapine versus haloperidol in the treatment of schizophrenia and schizoaffective and schizophreniform disorders: Results of an international collaborative trial American Journal of Psychiatry 154 1997 457 465
71. J. Unutzer, W. Katon, C.M. Callahan, J.W. Williams Jr., E. Hunkeler, and L. Harpole IMPACT investigators. Improving mood-promoting access to collaborative treatment Journal of the American Medical Association 288 22 2002 2836 2845
72. A. Wazana Physicians and the pharmaceutical industry: Is a gift ever just a gift? Journal of the American Medical Association 283 3 2000 373 380
73. K.B. Wells, C. Sherbourne, M. Schoenbaum, N. Duan, L. Meredith, and J. Unutzer Impact of disseminating quality improvement programs for depression in managed primary care: A randomized controlled trial Journal of the American Medical Association 283 2 2000 212 220
74. K. Wells, C. Sherbourne, M. Schoenbaum, S. Ettner, N. Duan, and J. Miranda Five-year impact of quality improvement for depression: Results of a group-level randomized controlled trial Archives of General Psychiatry 61 4 2004 378 386
75. C.J. Whittington, T. Kendall, P. Fonagy, D. Cottrell, A. Cotgrove, and E. Boddington Selective serotonin reuptake inhibitors in childhood depression: systematic review of published versus unpublished data Lancet 363 9418 2004 1341 1345
76. D.A. Wirshing, J.A. Boyd, L.R. Meng, J.S. Ballon, S.R. Marder, and W.C. Wirshing The effects of novel antipsychotics on glucose and lipid levels Journal of Clinical Psychiatry 63 10 2002 856 865
77. S.W. Woods Olanzapine and tardive dyskinesia British Journal of Psychiatry 175 1999 391 392
78. R.J. Wyatt, and I. de Saint Ghislain Economic savings and clozapine ([Letter]) American Journal of Psychiatry 152 4 1995 650 651